Insulin is necessary for the management of type 1 diabetes and is more commonly used for the medication of type 2 diabetes. The insulin pen was first launched over 20 years ago and has evolved to provide significant working advantages compared with the syringe and vial. Insulin Pen devices are now used by patients with diabetes globally, but there are marked geographic differences in the use of reusable and disposable pens. In many countries, syringe and vial are still the most popular method of delivering insulin, whereas, in many countries, the use of reusable or disposable pens is more common.
Request to get the report sample pages at : https://www.blueweaveconsulting.com/insulin-pen-market-bwc20010/report-sample
An electronic insulin pen was designed for diabetic patient’s dependent on insulin use in order to prevent wrong timing and wrong dosage caused by old age, vision, or mental illness. The insulin pen can be used electronically for routine dose injections and was designed to be able to used manually in the emergency. It is aimed that the patient can set the dose easily by using the fairly simple menu of the device. Additionally, the device was not designed as disposable, and the device was designed as reusable by changing the insulin tube.
Diabetes is a metabolic disorder in both the developed and developing countries. It is expected that about 371 million people have disease worldwide and this number has been estimated to rise up to 552 million by 2030. The rate of prevalence of diabetes is high in Asian countries. About 92.3 and 63 million people in China and India suffer from this metabolic disorder respectively. Diabetes (T2D) reduces the life expectancy by 5–10 years. Prevalence of diabetes is rapidly increasing worldwide due to interactions between environmental factors, genetic factors and lifestyle.
The insulin pen offers better convenience, flexibility, and quality of life results with pen devices as compared to the conventional insulin delivery devices.6 Dose accuracy with insulin pens was also reported to be better in many studies in comparison to vials and syringes method, especially at low doses (≤5 IU). All these factors are essential in improving patient adherence to the treatment and also reducing hypoglycemic episodes.
Enquire Before Purchase: https://www.blueweaveconsulting.com/insulin-pen-market-bwc20010/enquire-before-purchase
Insulin medication is deemed to be the center for the treatment of people who have diabetes, and in the United States, the adoption of insulin pens is increasing significantly as compared to the needles and syringes during the forecast period.
Asia-Pacific is also estimated to grow at a high CAGR during the forecast period due to the high population in China, India, and other Asian countries.
Insulin Pen market is fragmented due to the presence of number of large-sized companies, mid-sized & small-sized companies, and many start-ups that are working together to develop Insulin Pen. The leading companies of COVID-19 Test Kit Market are The leading companies of Insulin Pen Market are Owen Mumford, Ltd., Novo Nordisk A/S, Companion Medical, Berlin-Chemie Ag, Pendiq Gmbh, Emperra GmbH E-Health Technologies, Eli Lilly and Company, Ypsomed Ag, Sanofi, Biocon and other prominent players.
BlueWeave Consulting is a one-stop solution for market intelligences regarding various products and services online & offline. We offer worldwide market research reports by analyzing both qualitative and quantitative data to boost up the performance of your business solution.
Company Name: BlueWeave Consulting
Contact Person: Laltu
Email: Send Email
Phone: +1 866 658 6826
Address:Noida Sector 63